There are currently 16 active clinical trials seeking participants for Plaque Psoriasis research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and Ontario.
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/13/2024
Locations: Affiliated Dermatology, Scottsdale, Arizona +22 locations
Conditions: Plaque Psoriasis
Guselkumab Immunogenetics
Recruiting
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: UCSF Psoriasis and Skin Treatment Center, San Francisco, California
Conditions: Psoriasis Guttate, Plaque Psoriasis
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Recruiting
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and une... Read More
Gender:
Female
Ages:
All
Trial Updated:
03/05/2024
Locations: Evidera, a PPD Business Unit /ID# 238688, Morrisville, North Carolina +1 locations
Conditions: Plaque Psoriasis, Psoriatic Arthritis, Crohn Disease, Other Conditions for Which Risankizumab is an FDA-approved Treatment
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
Recruiting
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. Th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Wright State Physicians, Fairborn, Ohio
Conditions: Plaque Psoriasis, Vitamin D3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Medical Dermatology Specialists, Phoenix, Arizona +135 locations
Conditions: Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/27/2024
Locations: Center for Dermatology and Plastic Surgery, Scottsdale, Arizona +89 locations
Conditions: Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/27/2024
Locations: Medical Dermatology Specialists, Phoenix, Arizona +166 locations
Conditions: Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Recruiting
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/26/2024
Locations: Dermatology Research Associates, Los Angeles, California +9 locations
Conditions: Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Total Skin and Beauty Dermatology Center, Birmingham, Alabama +55 locations
Conditions: Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona +21 locations
Conditions: Plaque Psoriasis
Role of Insulin Action in Psoriasis Pathogenesis
Recruiting
The goal of this study is to collect more information from people with plaque psoriasis and to determine if insulin plays a role in the pathogenesis of psoriasis. The main question it aims to answer is if insulin action is preserved or even enhanced in psoriatic lesions despite insulin resistance elsewhere. Participants with plaque psoriasis will have punch biopsies taken of lesional and non-lesional skin after an overnight fast and then during an oral glucose tolerance test. Biopsy specimens wi... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/29/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Recruiting
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/20/2023
Locations: Cahaba, Birmingham, Alabama +25 locations
Conditions: Plaque Psoriasis